Real-world efficacy and safety of peptide receptor radionuclide therapy (PRRT) with 177Lu-Dotatate (Lutathera) (LU) in neuroendocrine tumors (NETs)

被引：0
|
作者：
Navarro Martin, M. [1 ]
Teran Brage, E. [1 ]
Campana-Diaz, E. [2 ]
Garcia-Talavera, P. [2 ]
Reguera Puertas, P. [1 ]
Rama-Alonso, S. [2 ]
Garijo-Martinez, M. C. [1 ]
Felix, L. C. [1 ]
Diaz Sanchez, P. [1 ]
Vidal Tocino, R. [1 ]
Fonseca Sanchez, E. [1 ]
机构：
[1] Univ Hosp Salamanca, Dept Med Oncol, Salamanca, Spain
[2] Univ Hosp Salamanca, Dept Nucl Med, Salamanca, Spain
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.227
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
219P
引用
收藏
页码：S95 / S95
页数：1
相关论文
共 50 条
  • [41] Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea
    Shin, Yeokyeong
    Moon, Bo Hyun
    Ryoo, Baek-Yeol
    Chang, Heung-Moon
    Kim, Kyu-pyo
    Hong, Yong Sang
    Kim, Tae Won
    Ryu, Jin-Sook
    Kim, Yong-il
    Yoo, Changhoon
    TARGETED ONCOLOGY, 2024, 19 (01) : 41 - 49
  • [42] In Vivo Instability of 177Lu-DOTATATE During Peptide Receptor Radionuclide Therapy
    Lubberink, Mark
    Wilking, Helena
    Ost, Amalia
    Ilan, Ezgi
    Sandstrom, Mattias
    Andersson, Camilla
    Fross-Baron, Katarzyna
    Velikyan, Irina
    Sundin, Anders
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (09) : 1337 - 1340
  • [43] 177Lu-Dotatate for Midgut Neuroendocrine Tumors
    Ozdemir, Nuriye Y.
    Arslan, Suheyla A.
    Sendur, Mehmet A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (14): : 1391 - 1391
  • [44] Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours
    Levart, D.
    Kalogianni, E.
    Corcoran, B.
    Mulholland, N.
    Vivian, G.
    EJNMMI PHYSICS, 2019, 6 (1)
  • [45] Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours
    D. Levart
    E. Kalogianni
    B. Corcoran
    N. Mulholland
    G. Vivian
    EJNMMI Physics, 6
  • [46] Prospective Cohort Real-World Study on Neuroendocrine Tumor Patient's Quality of Life During Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE
    Ramim, Jayda Eiras
    Matheos de Lima, Beatriz Arruda
    Bulzico, Daniel Alves
    Pujatti, Priscilla Brunelli
    Bergmann, Anke
    PANCREAS, 2022, 51 (07) : 784 - 789
  • [47] Safety and response after peptide receptor radionuclide therapy with 177Lu-DOTATATE for neuroendocrine tumors in phase 1/2 prospective Japanese trial
    Kudo, Atsushi
    Tateishi, Ukihide
    Yoshimura, Ryoichi
    Tsuchiya, Junichi
    Yokoyama, Kota
    Takano, Shoko
    Kobayashi, Noritoshi
    Utsunomiya, Daisuke
    Hata, Masaharu
    Ichikawa, Yasushi
    Tanabe, Minoru
    Hosono, Makoto
    Kinuya, Seigo
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2022, 29 (04) : 487 - 499
  • [48] Neuroendocrine Tumor Therapy: 177Lu-DOTATATE
    Mittra, Erik S.
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2018, 211 (02) : 278 - 285
  • [49] Dosimetric estimations using commercial workstations for peptide receptor radionuclide therapy (PRRT) patients treated with 177Lu-DOTATATE
    Mora Ramirez, E.
    Santoro, L.
    Trauchessec, D.
    Chouaf, S.
    Deshayes, E.
    Pouget, J.
    Kotzki, P.
    Bardies, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S810 - S810
  • [50] 177Lu-DOTATATE PRRT Safety and Organ-at-Risk Dosimetry in Patients With Gastroenteropancreatic Neuroendocrine Tumors
    Mileva, Magdalena
    Van Bogaert, Camille
    Marin, Gwennaelle
    Danieli, Rachele
    Artigas, Carlos
    Levillain, Hugo
    Ameye, Lieveke
    Taraji-Schiltz, Loubna
    Stathopoulos, Konstantinos
    Wimana, Zena
    Hendlisz, Alain
    Flamen, Patrick
    Karfis, Ioannis
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (09) : 847 - 853
12345